Minutes of meeting between the Association of the British Pharmaceutical Industry and the Committee on Safety of Medicines re report from the CSM the decline in yellow card reporting postmarketing surveillance studies validation of research studies research programmes on industrywide regulatory problems clinical site audits and inspections the status of current problems